Pfizer Inc. (NYSE: PFE) announced positive topline results from two Phase 3 trials evaluating its oral drug Litfulo (ritlecitinib) in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE